Kanwar Singh, MD
Interventional Cardiology · Charlottesville, VANPI 1073581666
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 98.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $11,711 and has fallen 72.8% since, to $3,190 in 2025.
Across 35 payments — averaging $432.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Siemens Medical Solutions USA, Inc.$97
- Boston Scientific$87
Across 19 payments — averaging $20,966 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$382K
- Philips North America LLC$16K
What the payments were for
- Speaking & faculty fees$6,50043%
- Travel & lodging$7,92352%
- Food & beverage$7185%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 32 | $14,957 |
| Siemens Medical Solutions USA, Inc. | 2 | $97 |
| Boston Scientific | 1 | $87 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$3,000
How this compares
$15,141 in reported general payments places this provider in the 75th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 14 | $12,292 |
| Atorvastatin Calcium | 25 | $525 |
| ClopidogrelClopidogrel Bisulfate | 12 | $29 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Charlottesville
- Angela TaylorCharlottesville$119K
- John SaxonCharlottesville$116K
- Michael RagostaCharlottesville$17K
- Saad GhummanCharlottesville$17K
- Deepak TalrejaVirginia Beach$1.5M
- Rajiv TayalFredericksburg$984K
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Noah JonesFalls Church$238K
- Michael GenVirginia Beach$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.